SKYE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SK

Mkt Cap

$7.0M

Volume

19.32K

Next Earnings

November 9th

Loading chart

SK

SKYESkye Bioscience, Inc. Common Stock

SKYE

Pay with—

Available Balance0.00

SK

Mkt Cap

$7.0M

Volume

19.32K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity ConferenceSkye Bioscience presented preclinical data on nimacimab, a CB1 receptor inhibitor antibody, showing significant additive weight loss effects when combined with tirzepatide and semaglutide in diet-induced obesity mouse models. The drug demonstrated durable weight loss after treatment discontinuation and reduced weight rebound by ~80% when used as maintenance therapy post-tirzepatide discontinuation. Skye is currently conducting a Phase 2a clinical trial combining nimacimab with GLP-1R agonists.GlobeNewswire Inc. · Jan 29, 2026

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc.(SKYE) ShareholdersLevi & Korsinsky has filed a securities class action lawsuit against Skye Bioscience, Inc. on behalf of shareholders who suffered losses between November 4, 2024 and October 3, 2025. The complaint alleges that defendants made false statements about the effectiveness of the company's lead product candidate, nimacimab, and overstated its clinical, regulatory, and commercial prospects. Investors who suffered losses during this period can request to be appointed as lead plaintiff by January 16, 2026.GlobeNewswire Inc. · Jan 16, 2026

SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYERosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects.GlobeNewswire Inc. · Jan 15, 2026

JYD DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYDRosen Law Firm is reminding investors in Jayud Global Logistics Ltd. (JYD), Skye Bioscience, Inc. (SKYE), and Klarna Group plc (KLAR) of upcoming lead plaintiff deadlines in securities class action lawsuits. The firm is encouraging affected investors to secure legal counsel to potentially recover losses from alleged fraudulent activities and misleading statements.GlobeNewswire Inc. · Jan 15, 2026

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. InvestorsSkye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.GlobeNewswire Inc. · Jan 14, 2026

SKYE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYERosen Law Firm is reminding investors in Skye Bioscience, Inc. (NASDAQ: SKYE) of the January 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects, causing investor damages when the true details emerged.GlobeNewswire Inc. · Jan 13, 2026

Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff AppointmentJohnson Fistel announces a class action lawsuit against Skye Bioscience for investors who purchased securities between November 4, 2024 and October 3, 2025. The lawsuit alleges the company made materially false and misleading statements about its drug candidate nimacimab, overstating its effectiveness and commercial prospects. Investors must seek lead plaintiff appointment by January 16, 2026.GlobeNewswire Inc. · Jan 12, 2026

SKYE FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYERosen Law Firm is reminding investors in Skye Bioscience, Gauzy Ltd., and Stride, Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false and misleading statements regarding their business operations and prospects. Investors who purchased securities during specified class periods may be entitled to compensation.GlobeNewswire Inc. · Jan 9, 2026

LRN DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Stride, Inc. Investors to Secure Counsel Before Important January 12 Deadline in Securities Class Action – LRNRosen Law Firm is notifying investors about securities class action lawsuits, with a January 12, 2026 deadline for lead plaintiff claims in the Stride, Inc. case. The lawsuit alleges that Stride made misleading statements about its products and services while inflating enrollment numbers, cutting staff costs improperly, and ignoring compliance requirements, resulting in investor damages.GlobeNewswire Inc. · Jan 9, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYERosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding nimacimab's effectiveness and commercial prospects, causing investor damages when the truth entered the market.GlobeNewswire Inc. · Jan 1, 2026

to start trading

SK

SKYESkye Bioscience, Inc. Common Stock

SKYE

Pay with—

Available Balance0.00

Your PositionYou don't own any SKYE yet.

Related Tickers

Earnings